The Buyer Pool Is Being Regulated, Not the Building
On August 26, 2026, Skilled Nursing News reported PitchBook data showing that the number of private-equity-involved healthcare deals has declined year over year, and that first-half 2026 deal value came in below the same period in 2025 ([Skilled Nursing News, August 26, 2026](https://skillednursingnews.com/2026/08/as-states-increase-oversight-of-pe-in-nursing-homes-deals-decline/)).
The instinct is to read that as a capital story — rates, spreads, risk appetite. It is not. Capital for skilled nursing has not disappeared. What changed is that approving a transaction has moved from a federal formality to a state-level review, and reviews take time and money.
PitchBook analysts put it plainly: the new state laws have produced longer and more costly deals across the care continuum, and consolidation is harder under tight state scrutiny. That is a transaction-execution finding, not an asset-quality finding. The buildings did not get worse. The path to closing on one got longer.
What The States Actually Did
California, Oregon and Rhode Island each have laws or regulations taking effect this year that require more documentation and transparency for mergers, acquisitions and other healthcare-sector transactions.
Connecticut went furthest and went specifically at nursing homes. In June 2026, Governor Ned Lamont signed what is characterized as one of the strongest state laws in the country on PE accountability in the sector. It requires PE-owned nursing homes to disclose their financial dealings with the state, and it bars PE firms from controlling day-to-day care decisions about residents. Lamont signed a companion bill curbing PE influence in hospitals, prompted by closures attributed to PE-owned health group financial decisions (Stateline, as reported by SNN).
Bills adding transaction oversight or limiting how PE can operate are pending in Hawaii, Indiana, New York, Pennsylvania, Vermont and Virginia.
That is ten states you can name. The reporting also says at least 25 states have proposed or passed laws increasing healthcare transaction oversight or restricting operational control by companies not run by clinicians.
The Gap Between 25 And 10 Is The Actual Finding
Ten named. At least twenty-five acting. The other fifteen were not enumerated in the reporting, and we are not going to guess at them.
That gap is the practical problem for anyone underwriting a skilled nursing acquisition right now. You cannot price an execution risk you cannot see, and a national summary that stops at ten examples is not a diligence document. If you are buying in a state you have not personally checked in the last ninety days, you do not know your filing regime — you know a headline about a category of law.
The operational consequence is specific and boring: pre-signing, someone on your side has to pull the current statute and any implementing regulation for the state the asset sits in, confirm whether a transaction notice or approval is required, and confirm the statutory clock. In states that adopted a notice-and-review regime, that clock is the closing date, whatever the purchase contract says.
Why This Shows Up In Distressed Assets First
Look at what actually cleared this summer.
A 202-bed Houston skilled nursing facility sold in July out of a court-approved bankruptcy process, opening at a $12.25 million stalking horse bid and closing at $15 million after two additional qualified bidders competed through multiple rounds — roughly a 22% premium to the opening bid, at about $74,300 per bed ([Skilled Nursing News, August 25, 2026](https://skillednursingnews.com/2026/08/skilled-nursing-dealbook-houston-nursing-home-sells-for-15m-multistate-provider-gets-30m-in-financing/)). The building was on CMS's Special Focus Facility Candidate List and carried an unused on-site dialysis unit and ventilator-capable infrastructure.
In the same week, a 125-bed South Carolina facility built in 1991, running at full licensed capacity with census reported above 90%, sold to a New York-based investor in a confidential transaction with no published price.
Two things are worth pulling out of that pair.
First, a competitive auction still worked. Distress plus a bankruptcy court plus a marketed process produced a 22% premium over the opening bid. Whatever is slowing regulated M&A, it is not suppressing bidding on assets that clear through a court.
Second, and less comfortable: one of the two prices is public and one is not. Confidential transactions are normal and always have been. But when the regulated, disclosed side of the market slows down, a larger share of what trades moves through bankruptcy dockets and private deals — and the comparable set available to the next appraiser gets thinner. Less public pricing is a second-order cost of transaction friction, and it lands on everyone who has to value one of these buildings.
The Case The States Are Making
It is worth stating the evidence honestly rather than treating this as pure regulatory drag.
PE investors have deployed roughly $1 trillion acquiring healthcare companies over the past decade (Commonwealth Fund). Proponents argue that capital fills genuine gaps, funding technology upgrades and process improvement — and in a sector this undercapitalized, that argument is not empty.
Against it: government and academic studies cited in the SNN reporting found PE involvement in nursing homes increased the death rate by 11%, and linked PE ownership to increased emergency room visits and rising Medicare costs. A 2022 Moody's Investors Service report found that nearly 90% of financially stressed healthcare companies were PE-owned.
We are reporting those figures as they were reported. The mortality finding in particular is the sort of number that gets quoted loosely, and anyone relying on it for a real decision should read the underlying studies rather than this summary.
What This Changes For An Operator-Buyer
The clearest read is that this legislation is not aimed at you if you are an owner-operator. Connecticut's law bars PE firms from controlling day-to-day care decisions. The broader wave restricts operational control by companies not run by clinicians. A regional operator buying a building to run it is, in most of these frameworks, the party the statute is written to prefer.
That is a competitive advantage, and it is a quiet one. When institutional capital faces a longer and more expensive path to closing, a credible operator who can close on contract terms gets more attention from sellers than its balance sheet alone would earn. The differentiator stops being price and becomes certainty of close.
Three things to actually do:
Check your own state, by name, before you sign. Not the national summary. The statute.
Put the regulatory clock in the contract. If a state notice or approval applies, the outside date has to accommodate it, and the earnest money should not go hard before the clock is understood.
Say the quiet part in your offer. If you are an operator rather than a fund, and the seller is weighing a bid from capital facing state review, your execution certainty is worth naming explicitly in the cover letter.
The Honest Limits Of This Piece
The PitchBook figures here are directional as reported — deal count down year over year, first-half value below 2025 — and we have not seen the underlying dataset or the sector cuts beneath the healthcare aggregate. "At least 25 states" is a floor, not a count, and fifteen of those states are unnamed in the source. Anyone using this to price a specific transaction should treat it as a prompt to go check a specific statute, which is the only version of this analysis that binds.
*Crawford Commercial Group Research. Sources are linked inline with their publication dates. We do not publish a figure we cannot attribute.*
Disclaimer: This report is provided for informational purposes only and does not constitute investment advice. Data sourced from Bureau of Reclamation, NIC MAP, American Lung Association, and other public institutional sources. Crawford Commercial Group Real Estate Group. April 2026.